-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, UroGen Pharma's UGN-301 Phase 1 Trial Shows Sustained Bladder Exposure And No Dose-Limiting Toxicities In Non-Muscle Invasive Bladder Cancer

Benzinga·04/28/2025 05:39:43
Listen to the news
  • UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation
  • UGN-301 formulated in a reverse thermal gel allowed sustained exposure in the bladder
  • Some patients receiving UGN-301 (zalifrelimab) intravesical solution showed clinical activity at the week 12 disease assessment
  • Data presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada